Status:
TERMINATED
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
Lead Sponsor:
University of California, San Francisco
Conditions:
Cholangiocarcinoma
Klatskin Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to test the safety of giving external beam radiation, followed by a Cyberknife radiosurgery boost at different dose levels, together with a chemotherapy drug called capeci...
Detailed Description
This is a dose escalation study which will escalate the dose of Cyberknife radiosurgery boost after external beam radiation of 45 Gy with concurrent capecitabine. The three dose levels are 4 Gy x5, 5 ...
Eligibility Criteria
Inclusion
- Age eighteen years or older
- Histological defined unresectable cholangiocarcinoma of hilar region of the liver
- Patients should have evaluable disease on one or more imaging modalities (CT scan, MRI, and/or PET) since this will be necessary for radiation treatment planning. However, because the borders of these tumors are sometimes difficult to define precisely, measurable disease is not required (see Section 9.1 for definitions of evaluable and measurable disease).
- The maximum tumor dimension should be less than 6 cm.
- Patients with pathologically enlarged perihepatic regional lymph nodes are allowed.
- Prior surgical resection is allowed if there is gross disease remaining
- Adjuvant chemotherapy is allowed at least 1 month after completion of radiation therapy if any grade 3 or higher toxicity has resolved
- Percutaneous biliary drains and biliary stents are allowed
- Performance status of ECOG 0-1 (see Appendix I)
- Life expectancy greater than 6 months
- Subject must have normal organ and marrow functions as defined below
- leukocytes \>3,000/mcL
- absolute neutrophil count \>1,500/mcL
- platelets \>100,000/mcL
- total bilirubin \<2.5 X institutional upper limit of normal
- AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal
- creatinine within normal institutional limits OR
- creatinine clearance \>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
- PT/PTT within normal institutional limits
- Gold marker seeds (1 to 3) are required to be placed in or around the primary tumor by an interventional radiologist
- Ability to give written informed consent and willingness to comply with the requirements of the protocol
- Women of child-bearing potential must agree to use an effective method of birth control during treatment and for six months after receiving their last dose of treatment
Exclusion
- Patients who have had prior chemotherapy
- Patients who have had external beam radiation to the region of liver hilar previously.
- Patients receiving any other investigational agents
- Patients with known metastases
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients who are not candidates for gold marker seeds placement due to position of the tumor or co-existing medical condition.
- Pregnant or lactating women and women of child-bearing potential who are not using an effective method of birth control
- Any condition that compromises compliance with the objectives and procedures of this protocol, as judged by the principal investigator
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00630890
Start Date
October 1 2007
End Date
December 1 2008
Last Update
September 11 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Francisco
San Francisco, California, United States, 94143-0226